Literature DB >> 19422397

The hepoxilins and some analogues: a review of their biology.

Cecil R Pace-Asciak1.   

Abstract

The hepoxilin pathway was discovered over two decades ago. Products in this pathway are derived through the 12S-lipoxygenase/hepoxilin synthase enzyme system and contain intrinsic biological activity. This activity relates to the reorganization of calcium and potassium ions within the cell, and in inflammation and insulin secretion. Although the natural hepoxilins are chemically unstable, chemical analogues (PBTs) have been synthesized with chemical and biological stability. The PBTs antagonize the natural hepoxilins. The PBTs showed bioavailability, excellent tolerance and stability in vivo. In proof of principle studies in vivo in animal models, the PBTs have shown actions as anti-inflammatory agents, anti-thrombotic agents, anti-cancer agents and anti-diabetic agents. These studies demonstrate the effectiveness of the base structure of the hepoxilin (and PBT) molecule and serve as an excellent framework for the design and preparation of second-generation compounds with improved pharmaceutical properties as therapeutics for the above-mentioned diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422397      PMCID: PMC2785520          DOI: 10.1111/j.1476-5381.2009.00168.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  A lipoxygenase product, hepoxilin A(3), enhances nerve growth factor-dependent neurite regeneration post-axotomy in rat superior cervical ganglion neurons in vitro.

Authors:  R K Amer; C R Pace-Asciak; L R Mills
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

2.  Biological actions of the free acid of hepoxilin A3 on human neutrophils.

Authors:  M Sutherland; T Schewe; S Nigam
Journal:  Biochem Pharmacol       Date:  2000-02-15       Impact factor: 5.858

3.  Actions of arachidonic acid and hepoxilin A3 on mammalian hippocampal CA1 neurons.

Authors:  P L Carlen; N Gurevich; P H Wu; W G Su; E J Corey; C R Pace-Asciak
Journal:  Brain Res       Date:  1989-09-11       Impact factor: 3.252

4.  Novel platelet antiaggregating substances.

Authors:  D Reynaud; A Sun; P Demin; C R Pace-Asciak
Journal:  Biochem Biophys Res Commun       Date:  2001-06-15       Impact factor: 3.575

5.  Hepoxilin analogs, PBT-3 and PBT-4, cause apoptosis of Gleevec-resistant K562 cells in vitro.

Authors:  Na Qiao; Denis Reynaud; Mohamed Abdelhaleem; Cecil R Pace-Asciak
Journal:  In Vivo       Date:  2007 Mar-Apr       Impact factor: 2.155

6.  A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition.

Authors:  Cecil R Pace-Asciak; Denis Reynaud; Peter Demin; Rukshana Aslam; Andrea Sun
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

7.  Hepoxilin analogs inhibit bleomycin-induced pulmonary fibrosis in the mouse.

Authors:  Robert P Jankov; Xiaoping Luo; Peter Demin; Rukshana Aslam; Vicky Hannam; A Keith Tanswell; Cecil R Pace-Asciak
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

8.  Direct modulation of Aplysia S-K+ channels by a 12-lipoxygenase metabolite of arachidonic acid.

Authors:  N Buttner; S A Siegelbaum; A Volterra
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

9.  The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cells.

Authors:  Na Qiao; Denis Reynaud; Peter Demin; Perry V Halushka; Cecil R Pace-Asciak
Journal:  J Pharmacol Exp Ther       Date:  2003-10-14       Impact factor: 4.030

10.  Formation and action of 8-hydroxy-11,12-epoxy-5,9,14-icosatrienoic acid in Aplysia: a possible second messenger in neurons.

Authors:  D Piomelli; E Shapiro; R Zipkin; J H Schwartz; S J Feinmark
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

View more
  11 in total

1.  Biosynthesis of 14,15-hepoxilins in human l1236 Hodgkin lymphoma cells and eosinophils.

Authors:  Asa Brunnström; Mats Hamberg; William J Griffiths; Bengt Mannervik; Hans-Erik Claesson
Journal:  Lipids       Date:  2010-10-29       Impact factor: 1.880

2.  Mediators and receptors in the resolution of inflammation: drug targeting opportunities.

Authors:  A G Stewart
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

3.  Electrospray MS/MS reveals extensive and nonspecific oxidation of cholesterol esters in human peripheral vascular lesions.

Authors:  Patrick M Hutchins; Ernest E Moore; Robert C Murphy
Journal:  J Lipid Res       Date:  2011-08-31       Impact factor: 5.922

Review 4.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.

Authors:  William S Powell; Joshua Rokach
Journal:  Biochim Biophys Acta       Date:  2014-10-29

5.  Human CYP2S1 metabolizes cyclooxygenase- and lipoxygenase-derived eicosanoids.

Authors:  Peter Bui; Satoshi Imaizumi; Sudheer Reddy Beedanagari; Srinivasa T Reddy; Oliver Hankinson
Journal:  Drug Metab Dispos       Date:  2010-11-10       Impact factor: 3.922

6.  Systematic analysis of rat 12/15-lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in inflammatory hyperalgesia.

Authors:  Ann M Gregus; Darren S Dumlao; Spencer C Wei; Paul C Norris; Laura C Catella; Flore G Meyerstein; Matthew W Buczynski; Joanne J Steinauer; Bethany L Fitzsimmons; Tony L Yaksh; Edward A Dennis
Journal:  FASEB J       Date:  2013-02-04       Impact factor: 5.191

Review 7.  Mammalian lipoxygenases and their biological relevance.

Authors:  Hartmut Kuhn; Swathi Banthiya; Klaus van Leyen
Journal:  Biochim Biophys Acta       Date:  2014-10-12

Review 8.  Lipoxygenase: an emerging target for stroke therapy.

Authors:  Klaus van Leyen
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-03       Impact factor: 4.388

9.  12/15-Lipoxygenase deficiency reduces densities of mesenchymal stem cells in the dermis of wounded and unwounded skin.

Authors:  S Hong; B V Alapure; Y Lu; H Tian; Q Wang
Journal:  Br J Dermatol       Date:  2014-07-17       Impact factor: 9.302

10.  The retinoid-related orphan receptor RORα promotes keratinocyte differentiation via FOXN1.

Authors:  Jun Dai; Yang Brooks; Karine Lefort; Spiro Getsios; G Paolo Dotto
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.